The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today

lung cancer

NOT Open Access | Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling

August 17, 2021 - 14:18 -- NOT Open Access
Author(s): 
Li Y, Xiao X, Wang H, Zhou Q, Jin Z, Zhang Y, Wang Y, Yue F, Zhou S, Yang J
Reference: 
Eur J Pharmacol. 2021 Aug 11:174411

Advanced Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a poor prognosis. The anti-malaria compounds dihydroartemisinin (DHA) have shown to regulate multiple targets and signaling pathways in cancers, but a global view of its mechanism of action remains elusive. In present study, we integrated network pharmacology and in vitro and in vivo experimental models to investigate the mechanisms of DHA in preventing NSCLC proliferation.

Subscribe to RSS - lung cancer